Business News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Roche snaps up BioImagene: Digital pathology laboratory equipment maker BioImagene is acquired by diagnostics firm Roche for $100 million under an agreement announced Aug. 23. BioImagene systems generate high-resolution, whole-slide digital images from glass microscope slides and incorporate software for image analysis. The deal builds on Roche's $3.4 billion acquisition in 2008 of tissue-based cancer test maker Ventana Medical Systems (1"The Gray Sheet" Jan. 28, 2008). By adding privately held BioImagene, Roche/Ventana "is uniquely positioned to improve laboratory efficiency and help pathologists improve patient care," the company said. "With BioImagene's current and future products, we will be able to deliver an end-to-end solution from automated staining to comprehensive patient reports.
You may also be interested in...
Cyberonics' Ambitious 5-Year Plan: Double Sales With New VNS Components
Cyberonics aims to double its sales to $320 million over the next five years by improving and adding new features to its VNS Therapy vagus nerve stimulation implant and entering new markets like Japan
Roche Finally Gets Nod With Sweetened $3.4 Billion Bid For Ventana
After seven months and a half-dozen attempts at acquiring tissue-based cancer test maker Ventana Medical Systems, Roche finally won over the firm's board with a sweetened bid worth $3.4 billion
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.